Estudo randomizado | Entre pacientes críticos com Covid-19, o tratamento com um agente antiplaquetário teve pouca propensão a melhorar os dias sem suporte de órgão em 21 dias.

Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial – JAMA

Editorial: Thromboinflammation and Antithrombotics in COVID-19: Accumulating Evidence and Current Status – JAMA

Comentário: Aspirin may improve 3-month survival for patients critically ill with COVID-19 – Imperial College London

Comentários no Twitter

In this bayesian randomized clinical trial, among critically ill patients with #COVID19, there was a low likelihood that treatment with an antiplatelet agent provided improvement in organ support–free days within 21 days. https://t.co/CnyWoOTn3Q

— JAMA (@JAMA_current) March 22, 2022